Business objectives have changed

The purpose of this study is to evaluate safety, tolerability, drug and food effects on relative bioavailability of BMS-986465 and its active derivative BMS-986464 in healthy participants and healthy participants of Japanese ethnicity.

Inclusion Criteria:

• Healthy male and female (i e, women not of childbearing potential) participants
• Body Mass Index (BMI) of 18 to 32 kg^m2 and total body weight ≥ 50 kg
• Parts A, B, and D: Participants without restriction on ethnicity
• Part C: Participants of Japanese ethnicity (both biological parents are ethnically Japanese)

Exclusion Criteria:

• Clinically significant medical, psychiatric and/or sound social reason, as determined by the investigator
• Any major surgery within 3 months of study intervention administration
• Participation in another clinical trial concurrent with this study

Note: Other protocol-defined inclusion/exclusion criteria apply

BMS will provide access to individual anonymized participant data upon request from qualified researchers, and subject to certain criteria. Additional information regarding Bristol Myer Squibb's data sharing policy and process can be found at: https://www.bms.com/researchers-and-partners/clinical-trials-and-research/disclosurecommitment.html